Archive for the ‘oncogene (journal)’ Category
Bharat Aggarwal is the last author on all three papers. He is now up to six corrections, two unexplained withdrawals, and two Expressions of Concern. He’s also threatened to sue us in the past, and has told us that his institution has been looking into his work.
Only one note specifies that the correction does not affect the paper’s conclusions.
First up: “Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling,” published in the International Journal of Cancer and cited 168 times, according to Thomson Scientific’s Web of Knowledge. The issues span two figures, according to the erratum note:
Oncogene is retracting a 2010 paper on the molecular details of breast cancer cells as they undergo metastasis following an investigation that discovered the first author had committed misconduct.
The thing is, the investigation concluded in 2012, and the paper — “miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers” — isn’t being retracted until next week.
According to Lucinda Haines, senior publishing manager at Nature Publishing Group, the paper will be retracted June 29.
We heard from Iris Behrmann, Head of the Life Sciences Research Unit at the University of Luxembourg:
A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.
Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Read the rest of this entry »
A group at the University of Texas Southwestern led by Adi F. Gazdar that found evidence of inappropriate image manipulation in a number of their papers has retracted its seventh and eighth studies.
Brutal honesty: Author takes to PubPeer to announce retraction — and tells us she’ll lose PhD, professorship
The comments suggested that the figures in the paper had problems. Some bands seemed to be duplicated, and one of the images looked very much like that of another paper.
Five of them appear in Molecular and Cellular Biology: Read the rest of this entry »
The article, “Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia,” was published online in September 2005 and has been cited 106 times, according to Thomson Scientific’s Web of Knowledge.
Why retraction notices matter: Group’s repeated misuse of figures gets different play from five journals
For some journals, thorough retraction notices are the rule — and, when misconduct is involved, the price authors pay for abusing the trust of the editors and the readers. Others seem to take a more casual approach. Guess which we think is best.
Consider the case of a group of researchers in China led by Tan Jinquan, an immune system expert at Wuhan University. Over the past two years or so, Jinquan and colleagues have lost no fewer than a half-dozen papers containing evidence of image manipulation. But, depending on the journal pulling the articles, you might not know it.
The U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) has found that a Boston University cancer researcher made up experiments reported in two papers funded by National Cancer Institute and National Institutes of Health grants. According to the ORI notice:
Sheng Wang, PhD, Boston University School of Medicine Cancer Research Center: Based on the Respondent’s acceptance of ORI’s research misconduct findings, ORI found that Dr. Sheng Wang, who has been an Assistant Professor, Department of Medicine, Boston University School of Medicine Cancer Research Center (BUSM), engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA102940 and R01 CA101992.
The two papers were: Read the rest of this entry »